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Background: Cardiac resynchronization therapy (CRT) reduces the mortality rate among patients with
advanced heart failure (HF) and a wide QRS complex. Despite such clinical improvement, the clinical
features of ventricular tachyarrhythmias (VA) and the risk of sudden cardiac death (SCD) among these
patients still remain to be elucidated.
Methods: In total, 128 consecutive patients with advanced HF (mean age, 68710 years; 90 men; mean left
ventricular ejection fraction [LVEF], 2777%) who underwent CRT with a cardioverter-deﬁbrillator (CRT-D)
as the primary prevention for SCD were examined. Twenty-nine patients had ischemic cardiomyopathy
(ICM), whereas the other 99 patients had nonischemic cardiomyopathy (NICM). At each follow-up
examination, patient- and device-related data were collected. All detected VA episodes were analyzed.
Results: During a mean period of 10097566 days, 30 patients (23%) experienced appropriate cardioverter-
deﬁbrillator treatment for sustained VA. Twenty-six had NICM and the other 4 had ICM. The ﬁrst VA
episodes mostly involved monomorphic ventricular tachycardia (VT) at 187730 beats/min (28 patients,
93%). The mode of successful therapy was antitachycardia pacing (ATP) in 60% of patients. Multiple linear
regression analysis revealed that among clinically plausible predictors (age; gender; LVEF; underlying
rhythms; QRS duration; QT interval; ischemic cause of HF; history of nonsustained VT; and the uses of
amiodarone, β-blockers, and renin-angiotensin inhibitors), only the history of nonsustained VT (Po0.0001)
was a signiﬁcant predictor of appropriate cardioverter-deﬁbrillator therapy.
Conclusions: After implantation of a CRT-D device for primary prevention, VAs were more prone to occur in
patients with nonischemic HF than in those with ischemic HF. Moreover, the ﬁrst VA episodes were mostly
monomorphic VT, and most episodes were terminated by ATP. In addition, nonsustained VT was a potent
predictor of VA after CRT.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Intraventricular conduction disturbance and atrioventricular,
intraventricular, and interventricular dyssynchrony are likely to
occur in severe heart failure (HF), and the vital prognosis worsens
as dyssynchrony progresses and the QRS width increases [1–3].
Cardiac resynchronization therapy (CRT) improves hemodynamics
by improving dyssynchrony and increasing the efﬁciency of
cardiac contraction, leading to improvement in the patient's
quality of life (QOL) and vital prognosis [4].
In the CArdiac REsynchronization-Heart Failure (CARE-HF) study
[5,6], CRT with a pacemaker (CRT-P) was found to decrease the
incidence of deaths from all causes and HF, and inhibited sudden
cardiac death in patients with HF, compared with optimal pharmaco-
logical therapy, demonstrating the effect of CRT on the vital prognosis
of patients with HF. The subjects of this study had advanced HF with
New York Heart Association (NYHA) classes III and IV, and these
outcomes may have been indicative of implantable cardioverter-
deﬁbrillator (ICD) for the primary prevention of sudden cardiac death
by ventricular tachyarrhythmias (VAs). However, the proarrhythmic
effect of CRT itself has been problematic—that is, the heterogeneity of
transmural repolarization from the left ventricular epicardial to
endocardial sides is increased by left ventricular epicardial pacing
after CRT, and the JT and Tpeak–Tend intervals prolong the QT interval,
resulting in the occurrence of VAs [7]. A subanalysis of the Comparison
of Medical Therapy, Pacing, and Deﬁbrillation in Heart Failure
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(COMPANION) study [8] revealed a 56% reduction in the risk of sudden
cardiac death in patients who underwent CRT with a deﬁbrillator
(CRT-D) compared with those who underwent pharmacological
therapy, which was associated with appropriate deﬁbrillator discharge
for ventricular tachycardia (VT) and ventricular ﬁbrillation (VF) in
11.6% at 1 year and 19.3% at 2 years. No predictive factors of lethal VAs
occurring after CRT have been established, and the Guidelines for Non-
Pharmacotherapy of Cardiac Arrhythmias [9] recommend CRT-D for
NYHA class III or IV patients with left ventricular ejection fraction
(LVEF) of r35%, wide QRS of Z120ms, and indications for ICD.
However, the role of CRT-D in the primary prevention of sudden
cardiac death in Japanese patients with advanced HF has not been
fully understood.
In the present study, we investigated the incidence of VAs
occurring after CRT-D device implantation and analyzed in detail
all the arrhythmic episodes in patients with advanced HF who
underwent CRT-D for the primary prevention of sudden cardiac
death. In addition, we investigated the clinical features and
predictive factors of VAs occurring after CRT-D.
2. Materials and methods
2.1. Study population
This study included 128 consecutive patients with advanced HF
complicated by intraventricular conduction disturbance. All
patients underwent CRT-D device implantation for HF and as the
primary prevention of sudden cardiac death between August 2006
and July 2012 at Hirosaki University Hospital. There were 90 men
and 38 women, and their mean age was 68710 years (Table 1).
The underlying disease was coronary artery disease in 29 patients
(23%), dilated cardiomyopathy in 77 patients (60%), hypertrophic
cardiomyopathy in 9 patients (7%), and sarcoidosis and other
diseases in 4 patients (3%). LVEF, measured by using left ventricu-
lography, was 2777.1% for all patients. None of the patients had
previous episodes of sustained VT or VF; however, 52 patients
(44%) had nonsustained VT (NSVT). β-Blockers were administered
in 109 patients (85%), angiotensin-converting enzyme inhibitors
(ACE-I) or angiotensin receptor blockers (ARB) were administered
in 96 patients (76%), and amiodarone was administered in 35
patients (27%). The CRT-D device was implanted according to the
Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias
issued by the Japanese Circulation Society [9]. This study was
approved by the medical ethics committee of our institution
(approved date was July 18th, 2013, approval number 2013-127).
2.2. Follow-up and device interrogation
The CRT-D device used was the Protecta XT CRT-D (Medtronic,
Inc., Minneapolis, Minnesota) in 18 patients; the Consulta CRT-D
(Medtronic, Inc.) in 23 patients; the Concerto (Medtronic, Inc.) in
22 patients; the InSync III Marquis (Medtronic, Inc.) in 3 patients;
the CONTAK (Guidant, Inc., St. Paul, Minnesota) in 34 patients; the
COGNIS (Boston Scientiﬁc, Natick, Massachusetts) in 22 patients;
the INCEPTA (Boston Scientiﬁc) in 1 patient; the Promote (St. Jude
Medical, St. Paul, Minnesota) in 3 patients; the ATLASþHF (St. Jude
Medical) in 1 patient; and the Unify (St. Jude Medical) in 1 patient.
After implantation of the CRT-D device, all patients visited the
outpatient clinic periodically or the device clinic every 3–6 months
for follow-up examination, and device-related data were collected
at these instances. Thirty-one patients (24%) used a remote mon-
itoring system: the CareLink Network (Medtronic Inc.) was used in
25 patients; the LATITUDE Patient Management System (Boston
Scientiﬁc) was used in 5 patients; and the Marlin.net Patient Care
Network (St. Jude Medical) was used in the remaining patient. In
these patients, the data were collected using the remote monitoring
systems through automatic monthly transmission. Device-related
data were also collected when patients unexpectedly visited the
outpatient clinic for symptomatic arrhythmic episodes and HF
symptoms. All VA events collected from the devices were analyzed.
Appropriate and inappropriate therapies were differentiated
through the assessment of intracardiac electrocardiograms, col-
lected from the devices, by several cardiologists. Moreover, we
analyzed the VA episodes to determine the type of detected VA
using the intracardiac electrocardiogram of the device. We distin-
guished between monomorphic VT and polymorphic VT or VF
by the regularity and morphology of the tachycardia.
2.3. End point and statistical analysis
The end point of this observational study was the ﬁrst occur-
rence of appropriate therapies. Most of the devices were pro-
grammed with their default settings.
All data are shown as mean7one standard deviation. For compar-
ison of the baseline characteristics, the t-test or analysis of variance
(ANOVA) was used for continuous variables, and the χ2 test was used
for nominal variables. To investigate the predictors for appropriate
deﬁbrillator therapy, the univariate analysis was performed using the
following variables: age; gender; LVEF; presence of ischemia; under-
lying rhythm; QRS width and QT time before CRT-D device implanta-
tion; past history of NSVT; and presence of amiodarone, β-blocker,
ACE-I, or ARB medication. A ﬁnal model was prepared with selected
variables with Po0.10, and multivariate analysis was performed using
the Cox proportional hazard model. A P value of o0.05 was regarded
as signiﬁcant in all tests. All statistical analyses were performed using
the JMP 9 Pro (SAS Institute Inc., Cary, North Carolina).
3. Results
3.1. Incidence of VAs after CRT-D device implantation
During a follow-up period of 10097566 days (range, 45–2661
days), appropriate CRT-D therapy for VAs was observed in 30 patients
(23%) (Fig. 1). Table 2 shows the comparison of clinical characteristics
between the 2 groups with (n¼30) and without appropriate ICD
therapy (n¼98). Of the 30 patients with appropriate ICD therapy, 26
(87%) had nonischemic cardiomyopathy(NICM) and the other 4 had
ischemic cardiomyopathy (ICM). Although the nonischemic origin was
Table 1
Clinical characteristics of the study patients.
Variable Total population (N¼128)
Age (years) 67710
Male gender 90 (70%)
ICM/NICM 29/99
Prevalence of NICM 77%
LVEF (%) 2777.1
Chronic AF rhythm 37 (29%)
QRS duration (ms) 162726
QT interval (ms) 449750
History of NSVT 52 (41%)
Medication
Amiodarone 35 (27%)
β-blocker 109 (85%)
ACE-I/ARB 97 (76%)
ICM, ischemic cardiomyopathy; NICM, nonischemic cardiomyopa-
thy; LVEF, left ventricular ejection fraction; AF, atrial ﬁbrillation;
NSVT, nonsustained ventricular tachycardia; ACE-I, angiotensin-
converting enzyme inhibitor; and ARB, angiotensin II receptor
blocker.
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more prevalent in patients with ICD therapy (87%) than in those
without therapy (74%), the difference was not statistically signiﬁcant
(P¼0.1688). The incidence of NSVT was signiﬁcantly higher in the
group with appropriate ICD therapy (70%) than in the group without
therapy (30%) (Po0.0001).
3.2. Type of ﬁrst VA episode after CRT-D and mode of successful
therapy
The median time from CRT-D implantation to the ﬁrst appro-
priate therapy was 496794 days (range, 20–1951 days). As shown
in Fig. 2, intracardiac electrocardiogram analysis of the device
demonstrated that the ﬁrst VA episode was monomorphic VT in 28
patients (93%), whereas the other 2 patients (7%) had polymorphic
VT or VF. The mean rate of monomorphic VT was 187730 beats/
min. The mode of successful therapy was antitachycardia pacing
(ATP) in 60% of patients. In the other 40% of patients, ATP was
ineffective and the VA was terminated by shock therapy.
3.3. Predictors of appropriate ICD therapy
As shown in Table 3, the univariate analysis using the Cox
proportional hazard model demonstrated that QRS duration
(P¼0.085), previous history of NSVT (Po0.001), and ACE-I/ARB
medication (P¼0.085) were signiﬁcant variables. The multi-
variate analysis using the Cox proportional hazard model after
adjusting for age and gender revealed that only a previous
history of NSVT was an independent predictor of appropriate
CRT-D therapy (Po0.001). In 20 patients, the heart rate of
NSVT before CRT-D device implantation could be analyzed, and
was found to be 153722 beats/min. The rate of sustained VT
after CRT-D device implantation in these patients was
190736 beats/min and was signiﬁcantly higher than that of
NSVT before implantation (P¼0.0011).
3.4. Impact of NSVT prior to CRT-D on the occurrence of sustained VA
and prognosis
As shown in Fig. 3, appropriate ICD therapy was observed in 23
of the 52 patients (44%) with a previous history of NSVT. In
contrast, only 7 of the 76 patients (9%) without a history of NSVT
experienced ICD therapy (Log rank test, Po0.0001). The all-cause
mortality was 49% (17/35) in the patients with a previous history
of NSVT, whereas it was only 9% (6/70) in those without a history
of NSVT. When the all-cause mortality was compared between
patients with and without appropriate ICD therapy, the morality
rate was 50% (15/30) in those with ICD therapy and 8% (8/98) in
those without ICD therapy (Log rank test, Po0.0001).
4. Discussion
By analyzing the device data in patients with advanced HF
implanted with CRT-D for primary prevention of sudden cardiac
death, we found that: 23% of the patients experienced appropriate
CRT-D therapy during a mean follow-up duration of 34 months;
many of the ﬁrst VA episodes involved monomorphic VT and were
treated by ATP; and NSVT was a potent predictor of sustained VAs
occurring after CRT-D.
4.1. Incidence of the ﬁrst VA episode after CRT-D as primary
prevention of sudden cardiac death
In patients who underwent CRT-D, particularly those under-
going this treatment for primary prevention of sudden cardiac
death, the rate of appropriate ICD therapy for VA was reported to
be 21% at 21 months (12%/year) after implantation in the study by
Soliman et al. [10], 15% at 16 months (11.3%/year) in the COMPA-
NION trial [8], and 21% at 18 months (14%/year) in the study by
Ypenburg et al. [11] In the present analysis, appropriate ICD
therapy was observed in 30 of 128 consecutive patients (23%)
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Fig. 1. Kaplan–Meier estimate of the time to ﬁrst appropriate ventricular tachy-
cardia (VT)/ventricular ﬁbrillation (VF) therapy in the primary prevention of
sudden cardiac death. ICD¼ implantable cardioverter-deﬁbrillator.
Table 2
Comparison of clinical characteristics between the patients with and without
appropriate implantable cardioverter-deﬁbrillator (ICD) therapy.
Variable Appropriate ICD
therapy (n¼ 30)
No appropriate ICD
therapy (n¼ 98)
P value
Age (years) 65710 68710 0.1080
Male gender 22 (73%) 68 (69%) 0.6790
ICM/NICM 4/26 25/73 0.1633
Prevalence of NICM 87% 74% 0.1633
LVEF (%) 2676.6 2777.1 0.3321
Chronic AF rhythm 11 (37%) 26 (27%) 0.2839
QRS duration (ms) 155728 164725 0.0876
QT interval (ms) 444758 450748 0.5379
History of NSVT 23 (77%) 29 (30%) o0.0001
Medication
Amiodarone 10 (33%) 25 (26%) 0.4003
β-blocker 24 (80%) 85 (87%) 0.3640
ACE-I/ARB 26 (87%) 71 (73%) 0.1290
ICM, ischemic cardiomyopathy; NICM, nonischemic cardiomyopathy; LVEF, left
ventricular ejection fraction; AF, atrial ﬁbrillation; NSVT, nonsustained ventricular
tachycardia; ACE-I, angiotensin-converting enzyme inhibitor; and ARB, angiotensin
II receptor blocker.
polymorphic VT/VF
defibrillation
(7%)
(33%)
cardioversion
ATPmonomorphic VT
(N = 28, 93%) (N = 18, 60%) 
(N = 2, 7%) 
Fig. 2. Clinical features of the ﬁrst appearing ventricular tachyarrhythmias
after cardiac resynchronization therapy (Panel A) and the mode of successful
therapy (Panel B). VT¼ventricular tachycardia; VF¼ventricular ﬁbrillation; and
ATP¼antitachycardia pacing.
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during the 34-month period (8.1%/year), showing a similar rate to
or slightly lower rate than those reported previously [8,10,11],
despite the fact that the present study had a much higher number
of patients with NICM than those in previous studies [8,10,11].
Of the patients experiencing appropriate ICD therapy after implan-
tation in the present study, 26 patients (87%) had NICM as the
underlying disease, whereas only 4 (13%) had ICM. This was
related to the characteristics of the patients in the present study
—NICM was noted among 77% of the patients in the present study,
which was much higher than that noted in Caucasian studies (45%
in MADIT-CRT [12]). Previous Japanese cohort studies [13,14]
demonstrated that the vital prognosis of Japanese patients with
myocardial infarction was favorable, and the rate of sudden cardiac
death was low compared with those in the MADIT-II study [15].
Iles et al. [16] reported that patients with NICM and myocardial
ﬁbrosis, detected by late gadolinium enhancement (LGE) on
cardiac magnetic resonance imaging (CMRI), had an ICD therapy
rate that was as high as that among patients with ICM; however,
the patients in both of these groups exhibited a signiﬁcantly
higher risk than those without LGE on CMRI—that is, as the
disease advances, the risk of ICD therapy increases.
4.2. Clinical features and predictors of VA after CRT
Soliman et al. [10] reported that NSVT detected before CRT is an
independent predictor of appropriate deﬁbrillator therapy. Our
results in Japanese patients were consistent with previous ﬁnd-
ings, and multivariate analysis demonstrated that NSVT detected
before CRT-D device implantation was an independent predictor of
VA appearing after CRT-D. However, although several previous
studies [8,10] reported that reduced LVEF and QRS width were also
predictors, we found no predictive signiﬁcance in these indices.
A recent study from Manfredi et al. [17] demonstrated that in
patients with a primary prevention indication for CRT-D, the
estimated 2-year risk of appropriate ICD therapy is 3.3%, 2.5%,
and 1.9% for a post-CRT-D LVEF of 45%, 50%, and 55%, respectively.
When a CRT responder demonstrates near normalization in LVEF
to Z45%, the incidence of ICD therapy for VA becomes low. The
observation period was longer in our study (mean, 34 months)
than in the others, and patients who showed improved or
aggravated LVEF compared with that at the time of implantation
may have been included in our study, both of which may have
inﬂuenced our analysis. In addition, favorable narrower QRS might
have been obtained with improved dyssynchrony after CRT-D in
some patients. Thus, the QRS width did not seem to be a
signiﬁcant predictor in the present study. NSVT, as an independent
predictor, indicates the presence of arrhythmogenic substrate
before CRT-D device implantation.
VA episodes occurring after CRT-D mostly involved mono-
morphic VT, and more than half of the episodes could be
terminated by ATP before shock therapy, suggesting that the
mechanism of the present VA involves reentry occurring in the
arrhythmogenic substrate that was already present before CRT-D.
At the same time, approximately half of the monomorphic VT
occurring for the ﬁrst time after CRT-D failed to be terminated by
ATP. We believe that there are several reasons for this failure of
termination. First, it may be related to the mechanism of VT.
Theoretically, ATP is considered to be effective for almost all
cases of reentrant tachycardia [18–21]. Thus, it was possible that
the mechanism of some monomorphic VT involved enhanced
Table 3
Cox proportional hazard regression analysis of clinical parameters: predictor of ventricular tachyarrythmias.
Variable Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (years) 0.9832 0.9576–1.0171 0.2643
Male gender 1.2189 0.5635–2.9228 0.6261
NICM 1.8966 0.7374–6.4348 0.1992
LVEF (%) 0.9710 0.9230–1.0195 0.2401
Chronic AF rhythm 1.6731 0.7693–3.4628 0.1867
QRS duration (ms) 0.9875 0.9735–1.0017 0.0846 0.9914 0.9764–1.0064 0.2589
QT interval (ms) 0.9986 0.9910–1.0060 0.7128
History of NSVT 5.2247 2.3570–13.1790 o0.0001 5.2879 2.3724–13.3927 o0.0001
Amiodarone 1.3534 0.6070–2.8282 0.4435
β-blocker 0.5826 0.2527–1.5783 0.2650
ACE-I/ARB 2.3208 0.8981–7.899 0.0858 2.5379 0.9700–8.7112 0.0586
ICM, ischemic cardiomyopathy; NICM, nonischemic cardiomyopathy; LVEF, left ventricular ejection fraction; AF, atrial ﬁbrillation; NSVT, nonsustained ventricular
tachycardia; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; and CI, conﬁdence interval.
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Fig. 3. Impact of nonsustained ventricular tachycardia (NSVT) before cardiac resynchronization therapy on the occurrence of sustained ventricular tachyarrhythmias (VA)
(Panel A) and all-cause mortality (Panel B). VT¼ventricular tachycardia; and VF¼ventricular ﬁbrillation.
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automaticity and not reentry. Second, it may have been inﬂuenced
by the ICD setting. Although the ﬁrst VA episode after CRT-D
device implantation involved reentrant VT, it was possible that
ATP was not able to capture the tachycardia, which could be
treated if the ICD was set to have increased pacing or shorter
pacing intervals.
ICD is generally programmed only for VF treatment in cases of
primary prevention. Since the VA episodes detected mostly
involved sustained monomorphic VT in the present analysis, we
believe that ATP should be programmed in the device setting for
CRT-D, which is performed for primary prevention of sudden
cardiac death, especially in patients with NICM, as evidenced in
the present study.
4.3. Study limitations
This is a retrospective, observational study performed at a
single institution. Since the end point was appropriate ICD
therapy, it is possible that because of the device treatment setting,
an overtreatment with ATP or shock therapy by the device might
have been applied to self-terminating VA. The presence or absence
of NSVT before CRT-D was estimated by 24-h Holter monitoring
before CRT-D implantation, and therefore, false-negative cases for
NSVT may be present in our cohort.
5. Conclusions
Appropriate ICD therapy for VA occurred in approximately 20%
of patients with advanced HF during the 34-month follow-up
period after CRT-D device implantation for the primary prevention
of sudden cardiac death, and the rate of the therapy increased with
time. The ﬁrst VA episodes after CRT mostly involved mono-
morphic VT, and most episodes were terminated by ATP, indicating
the necessity of ATP in the setting of the device. Finally, NSVT was
a signiﬁcant predictor of the appropriate ICD therapy after CRT-D.
Moreover, aggressive drug therapy including β-blockers and amio-
darone would be helpful in such patients.
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